
Full OptIMMize-1 results show high skin clearance rates with risankizumab in children and teens with psoriasis, sustained through 52 weeks.
Children who exceed their expected share of infections conjure up a host of differential diagnoses, from allergies to a primary immune defect. The authors walk you through the workup you need to do to get at the source of the problem.






